Literature DB >> 12464262

Characterization of the CYP4A11 gene, a second CYP4A gene in humans.

Aouatef Bellamine1, Yarong Wang, Michael R Waterman, James V Gainer, Elliot P Dawson, Nancy J Brown, Jorge H Capdevila.   

Abstract

Comparison between the cDNA sequence of CYP4A11 and that deduced from a published genomic clone suggested the presence of an additional CYP4A gene in humans, CYP4A22. PCR amplification of genomic DNA yielded overlapping clones covering 13kb of genomic DNA and extending from 1003bp upstream from CYP4A11 translation initiation to 135bp upstream of the mRNA polyadenylation signal. Sequence and Southern blot analysis showed the presence in humans of two highly homologous CYP4A genes, CYP4A11 and CYP4A22. These two genes share 96% sequence identity and have similar intron/exon sizes and distribution. Short nucleotide insertions (< or =10bp) in introns 1, 3, 9, and 11, and deletions (< or =18bp) in introns 4, 6, and 11 differentiate the two genes. RT-PCR amplification of human kidney RNA followed by restriction fragment analysis showed that CYP4A11 is the predominant isoform expressed in kidney.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12464262     DOI: 10.1016/s0003-9861(02)00545-3

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  9 in total

1.  Mouse Cyp4a isoforms: enzymatic properties, gender- and strain-specific expression, and role in renal 20-hydroxyeicosatetraenoic acid formation.

Authors:  Dominik N Muller; Cosima Schmidt; Eduardo Barbosa-Sicard; Maren Wellner; Volkmar Gross; Hantz Hercule; Marija Markovic; Horst Honeck; Friedrich C Luft; Wolf-Hagen Schunck
Journal:  Biochem J       Date:  2007-04-01       Impact factor: 3.857

2.  Arachidonic acid ω-hydroxylase CYP4A11: inter-ethnic variations in the 8590T>C loss-of-function variant.

Authors:  Christian Lacks Lino Cardenas; Aurore Devos; Aminata Toure; Jaime Cardenas Garcia; Abderraouf Kenani; Florence Migot-Nabias; Franck Broly; Dany Chevalier
Journal:  Mol Biol Rep       Date:  2011-05-27       Impact factor: 2.316

Review 3.  Arachidonic acid monooxygenase: Genetic and biochemical approaches to physiological/pathophysiological relevance.

Authors:  Jorge H Capdevila; Wenhui Wang; John R Falck
Journal:  Prostaglandins Other Lipid Mediat       Date:  2015-05-15       Impact factor: 3.072

4.  CYP4A/20-HETE regulates ischemia-induced neovascularization via its actions on endothelial progenitor and preexisting endothelial cells.

Authors:  Li Chen; Samantha Tang; Frank F Zhang; Victor Garcia; John R Falck; Michal L Schwartzman; Ali S Arbab; Austin M Guo
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-04-05       Impact factor: 4.733

Review 5.  20-HETE and blood pressure regulation: clinical implications.

Authors:  Cheng-Chia Wu; Tanush Gupta; Victor Garcia; Yan Ding; Michal L Schwartzman
Journal:  Cardiol Rev       Date:  2014 Jan-Feb       Impact factor: 2.644

6.  Expression of cytochrome P-450 4 enzymes in the kidney and liver: regulation by PPAR and species-difference between rat and human.

Authors:  Osamu Ito; Yasuhiro Nakamura; Liping Tan; Tsuneo Ishizuka; Yuko Sasaki; Naoyoshi Minami; Masayuki Kanazawa; Sadayoshi Ito; Hironobu Sasano; Masahiro Kohzuki
Journal:  Mol Cell Biochem       Date:  2006-03-22       Impact factor: 3.396

7.  The porcine taurochenodeoxycholic acid 6alpha-hydroxylase (CYP4A21) gene: evolution by gene duplication and gene conversion.

Authors:  Kerstin Lundell
Journal:  Biochem J       Date:  2004-03-15       Impact factor: 3.857

8.  Targeting 20-HETE producing enzymes in cancer - rationale, pharmacology, and clinical potential.

Authors:  Anna Alexanian; Andrey Sorokin
Journal:  Onco Targets Ther       Date:  2013-03-26       Impact factor: 4.147

9.  Kinetic analysis of lauric acid hydroxylation by human cytochrome P450 4A11.

Authors:  Donghak Kim; Gun-Su Cha; Leslie D Nagy; Chul-Ho Yun; F Peter Guengerich
Journal:  Biochemistry       Date:  2014-09-19       Impact factor: 3.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.